Skip to content

Clinical Trial

Learn About Enrollment in a Clinical Trial Sponsored by Conformal

The Conformal Early Feasibility Study is an evaluation of the safety and performance of the Conformal LAA Seal (CLAAS). This is a prospective, multicenter, open-label, first-in-human study.

The study will enroll up to 45 adults aged 18 or older with documented non-valvular atrial fibrillation and high risk of stroke or systemic embolism, who have been advised to take oral anticoagulation therapy, but have appropriate reasons to seek a non-pharmacologic alternative.

There are other criteria for participation in this study. For more information, visit

Participating Sites

New Hampshire
Catholic Medical Center
Manchester, New Hampshire
Contact:  Elizabeth Cornelius, RN
Principal Investigator: Jamie Kim, M.D.

New York
Columbia University Medical Center/NYPH
New York, New York
Contact: Efrain DeJesus
Principal Investigator: Robert Sommer, M.D.

Bryn Mawr Hospital
Bryn Mawr, Pennsylvania
Contact: Lisa Thome, MS
Principal Investigator: Sheetal Chandhok, M.D.

The Heart Hospital Baylor Plano
Plano, Texas
Contact: Gina Ortiz
Principal Investigator: Molly Szerlip, M.D.

Pacific Heart Institute
Santa Monica, CA
Contact: Crystal Ducharme
Principal Investigator: Shephal Doshi, M.D.

Smiling Dr. with arms crossed